Bon Natural Life Limited unveils pricing of upsized US$11 million initial public offering25/6/2021 KUALA LUMPUR, June 24 -- Bon Natural Life Limited (BON) has announced the pricing of its firm commitment initial public offering of 2,200,000 ordinary shares, par value US$0.0001 per share (the Shares) at a public offering price of US$5.00 per Share (the Offering). (US$1 = RM4.162)
This is for total gross proceeds of US$11.0 million, before deducting underwriting discounts, commissions and other related expenses, according to a statement. In addition, BON has granted the underwriters a 45-day option to purchase up to an additional 330,000 Shares at the public offering price, less underwriting discount and commissions. The Shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol ‘BON’ on June 24, whereby the Offering is expected to close on or about June 28, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds for working capital, to expand their sales and distribution network, research and development, and to expand production capacity. US Tiger Securities Inc and Newbridge Securities Corporation are acting as co-lead book running managers, and R.F. Lafferty & Co Inc is acting as the joint lead book running manager. BON is one of the leading bio-ingredient solutions providers in the natural, health and personal care industries. More details at www.bnlus.com. -- BERNAMA
0 Comments
PETALING JAYA, June 25 (Bernama) -- Malaysia Productivity Corporation (MPC) and the Special Taskforce to Facilitate Business (PEMUDAH) laud the swift and proactive action by Jabatan Bomba dan Penyelamat Malaysia (JBPM) in issuing a circular that allows deeming provision granting automatic clearance for newly completed building fire safety inspection. A circular dated 24 May 2021 stated that “if JBPM does not issue any comment or clearance letter within 14 days from the date of inspection and if during the closing of the inspection, no action needs to be taken by the Principal Submitting Person (PSP) or Submitting Person (SP), the clearance letter for the inspections of Passive Design (Form G8) and Active System (Form G9) deemed to have been issued for the purpose of the Certificate of Completion and Compliance (CCC) issuance”.
The 14-day deeming clause by JBPM enhances business and government efficiency. JPBM’s action was responding to challenges caused by the impact of COVID-19 on the construction industry as voiced by the players through PEMUDAH. The decision improves the ease of doing business for the construction industry. Dato’ Abdul Latif Haji Abu Seman, Director General of MPC, which serves as the Secretariat for PEMUDAH commented, “JBPM’s decision creates a positive domino effect in the process and improves the overall productivity and performance. During this difficult time when businesses are facing various challenges, regulators need to be flexible and fast to act to facilitate firms’ operations. I commend JPBM’s quick handling of the CCC matter. This helps construction companies to be more productive.” PEMUDAH Co-chair, Dato’ Dr. Ir. Andy Seo Kian Haw echoed DG MPC’s statement, “PEMUDAH’s role is to improve the ease of doing business. We understand that COVID-19 has disrupted business operation in all sectors where challenges and issues are inevitable. When businesses concern regarding CCC was brought up to PEMUDAH, JBPM responded by issuing the deeming clause. This must be quoted as an exemplary effort in regulation being agile enough to navigate and adapt to challenges. Malaysia ranked second among 190 economies in dealing with construction permits according to World Bank’s Doing Business report 2020. I must emphasise that what happen on ground should reflect this standing and action by JBPM must be emulated.” Dato’ Andy said. The construction business community welcomes JBPM’s timely action. Datuk Ezumi Harzani Ismail, President of Malaysian Institute of Architects (PAM) praised JPBM’s decision, “During this challenging period, we need agile and proactive approaches in our regulatory environment to be more responsive to the situation to help businesses to operate well by minimising regulatory challenges. The industry is grateful that the deeming provision indeed will accelerate the process in issuing CCC.” On 24 May 2021, JBPM Director General issued the said circular to the local authorities and industry associations to abide by the decision. JPBM addressed recommendation made by PEMUDAH which which involve relevant government bodies, and representatives from the private sector, under PEMUDAH’s Technical Working Group on Dealing with Construction Permits (TWGDCP). About Malaysia Productivity Corporation (MPC) Malaysia Productivity Corporation (MPC) is a statutory body under the Ministry of International Trade and Industry (MITI). MPC promotes productivity, quality and competitiveness to the industries and organisations in Malaysia. MPC's vision is to be the leading organisation in productivity enhancement for global competitiveness and innovation. Released by MALAYSIA PRODUCTIVITY CORPORATION Source: MALAYSIA PRODUCTIVITY CORPORATION (MPC) FOR MORE INFORMATION, PLEASE CONTACT: Name: Huda Atiqah Samsir Tel: 0137261950 Email: [email protected] Name: Nik Haneez Amizan Nik Rosdi Tel: 0197181804 Email: [email protected] --BERNAMA KUALA LUMPUR, June 24 (Bernama) -- Echodyne has announced substantial enhancements to its industry-leading radars, adding a new radar for international markets, new product for special operations-type applications, ruggedised radome, and continuing improvements in software and performance.
Together, these product developments represent significant advancements to its breakthrough radar technology, MESA®, according to a statement. With customers in defence, national security, and critical infrastructure protection, Echodyne radars have become a core component for counter-UAS, border security, and base and perimeter 3D surveillance solutions. “We continue to find excellent customer traction for our high-performance radars and are excited to add these new products and enhancements to the EchoGuard family,” said Echodyne Chief Executive Officer, Eben Frankenberg. “We are scaling our business to, not only meet demand but to become the leading radar manufacturer for a range of current and future defence and security applications. There is a lot more to come and we’re excited about our next phase.” The products and improvements include EchoGuard International. The new EchoGuard radar has RoHS3 construction and is compliant with CE Radio Equipment Directive (RED) compliance for EU customers, per Type Examination Certificate per 2014/53/EU Radio Equipment directive. With EchoGuard spectrum expansion, many jurisdictions allow for RadioLocation use at 24.05-24.25 GHz, and EchoGuard now has a new product variant to address these markets. The products and improvements also include improved radome; Lightweight Deployment Kit (LDK); firmware updates; new waveform ideal for slow velocity resolution; and, RadarUI update. Echodyne, the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. -- BERNAMA New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region
BILLERICA, Mass., June 24 (Bernama-GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical). Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal® CR & PS total knee replacement systems, iTotal® CR & PS patella devices, and iUni® and iDuo® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future. XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries. “This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.” The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas. The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com. Cautionary Statement Regarding Forward-Looking Statements Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Source: Conformis, Inc. Media Contact: Investor Relations [email protected] (781) 374-5598 Source: Conformis, Inc. --BERNAMA KUALA LUMPUR, June 22 (Bernama) -- Nippon Express (China) Co Ltd (NE China), a local subsidiary of Nippon Express Co Ltd has opened and begun operations at new logistics locations in Jiashan, Hangzhou and Changshu in the Yangtze River Delta.
As part of China's national strategy, integrated development has been pursued in the Yangtze River Delta, comprising 16 cities in the lower reaches of the Yangtze River in Shanghai, Jiangsu Province and Zhejiang Province. This has drawn in numerous companies not only from the electric appliance, electronics, automotive, equipment and other industries but also from the domestic demand-oriented retail and apparel industries that serve local consumers. Taking a holistic approach to the Yangtze River Delta, NE China has set up the three new logistics centres in Jiashan, Hangzhou and Changshu to handle automotive parts and general consumer goods. This is also to develop high-quality logistics services offering uniform operational quality across all locations with an eye to beginning handling medical equipment, according to a statement. Moving forward, NE China will be looking to actively introduce automated transport equipment and other cutting-edge technologies to save on labour. It will also establish a forklift training centre to improve handling techniques and safety, aimed at establishing model warehouses in China that represent an ideal fusion of hardware and software. More details at http://www.nipponexpress.com/ -- BERNAMA |
Archives
April 2023
|